Cílená léčba chronické myeloidní leukemie
| Title in English | Targeted treatment of chronic myeloid leukaemia |
|---|---|
| Authors | |
| Year of publication | 2023 |
| Type | Article in Periodical |
| Magazine / Source | Profi Medicína |
| MU Faculty or unit | |
| Citation | |
| Web | https://profimedicina.cz/cilena-lecba-chronicke-myeloidni-leukemie/ |
| Keywords | chronic myeloid leukemia; therapy; HALF |
| Description | The prognosis of patients with chronic myeloid leukemia has undergone a radical improvement thanks to modern treatment aimed at the essence of the disease, introduced into clinical practice at the beginning of the millennium. The range of 5 BCR::ABL1 tyrosine kinase inhibitors – imatinib, nilotinib, dasatinib, bosutinib and ponatinib – has recently been expanded to include asciminib, whose different mechanism of action suggests combining efficacy with a reduced burden of side effects. |